ReviewInternational journal of nanomedicine2025
Application of Nanotechnology in TACE Treatment of Liver Cancer.
Review in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Oxidative Stress-Guided Gold Nanoparticles for Cancer Theranostics.Antioxidants (Basel, Switzerland) · 2026Review
- Application of multimodal nanotechnology and standardized nursing management in ventricular arrhythmia.Biomedical engineering online · 2026Review
- [Exploration and application of nanotechnology in precision transarterial chemoembolization for hepatocellular carcinoma].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Review
- Analysis of survival prognosis and influencing factors in patients with primary liver cancer after D-TACE: a retrospective cohort study.BMC gastroenterology · 2026Article
- Sequential-Delivery Gel Microspheres Integrating HAase-Mediated ECM Remodeling and GA-Active Targeting for Deep Tumor Penetration in TACE-Treated HCC.International journal of nanomedicine · 2026Article
- Calcification-Mediated Dual-Starvation and Immune Activation for Transarterial Chemoembolization.International journal of nanomedicine · 2026Article
- Targeting Multiple Pathophysiological Axes in COPD: Nanomaterial Advances.International journal of nanomedicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver cancer, particularly hepatocellular carcinoma (HCC), remains a global health challenge with limited therapeutic options for advanced stages. Transarterial chemoembolization (TACE), the first-line treatment for intermediate and advanced-stage HCC, faces limitations such as incomplete tumor embolization and systemic toxicity. This review synthesizes recent advancements in nanotechnology to address these challenges, focusing on nanoparticles (NPs) as embolic agents, drug carriers, and imaging contrast agents. Nanoparticle-based drug delivery systems (eg, gold NPs, liposomes) enable localized drug release in tumors, enhancing chemotherapy efficacy while minimizing systemic side effects. Multimodal imaging NPs (eg, superparamagnetic iron oxide NPs, gadolinium-based NPs) enhance real-time visualization of tumor vasculature during TACE, facilitating precise embolization and treatment monitoring. Additionally, combining NPs with photothermal therapy or anti-angiogenic agents (eg, sorafenib) demonstrates synergistic effects in inhibiting tumor recurrence and metastasis. In conclusion, nanotechnology significantly enhances TACE's precision and efficacy through targeted delivery and multimodal imaging, though challenges in biocompatibility, safety, stability, and large-scale production require urgent attention. Future studies should focus on developing multifunctional nanocarriers and personalized nanomedicine strategies to optimize clinical outcomes for HCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.